The targets used for CAR-NK research in preclinical studies include CD19, CD20, CD138, CD5, CD2 subset 1 (CS1), NKG2D ligand, glucosylceramidase beta (GD2), HER2, epidermal growth factor receptor (EGFR), EGFRvIII, epithelial cell adhesion molecule 1, glypican 3, and guanine nucleotide-binding protein alpha-7 to target distinct cancer cell types (Rezvani et al., 2017). This evidence concerns the gene SLAMF7 and cancer.